Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by WEN-JEN HWU and SCOTT ERIC WOODMAN.
WEN-JEN HWU
Connection Strength
0.623
SCOTT ERIC WOODMAN
  1. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.052
  2. Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107.
    View in: PubMed
    Score: 0.044
  3. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.043
  4. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.043
  5. Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 10 11; 6(1):103.
    View in: PubMed
    Score: 0.043
  6. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.043
  7. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.042
  8. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283.
    View in: PubMed
    Score: 0.041
  9. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.041
  10. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.038
  11. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.036
  12. Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunol Res. 2015 Nov; 3(11):1201-6.
    View in: PubMed
    Score: 0.034
  13. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.034
  14. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.032
  15. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma. Melanoma Res. 2014 Aug; 24(4):342-8.
    View in: PubMed
    Score: 0.032
  16. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. J Cutan Pathol. 2012 Sep; 39(9):821-5.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.